The potential therapeutic benefit of targeting ADAMTS13 activity

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 1, 2014, Pages 28-33

  Eerenberg, Elise S ^a   Levi, Marcel ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

ADAMTS13; thrombotic microangiopathy; von Willebrand factor

Indexed keywords

VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE HEART INFARCTION; ANTICOAGULATION; ARTICLE; BRAIN ISCHEMIA; CONCENTRATION (PARAMETERS); ENZYME ACTIVITY; FIBRINOLYSIS; HELLP SYNDROME; HUMAN; HYPERTENSION; INFECTION; LIVER DISEASE; MALARIA FALCIPARUM; MALIGNANT HYPERTENSION; ONCOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; SEPSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREMIA; VENOUS THROMBOEMBOLISM;

ADAM PROTEINS; ANIMALS; HEMOSTASIS; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 84893088715     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1363156     Document Type: Article

References (46)

1. Crawley J. T., de Groot R., Xiang Y., Luken B. M., Lane D. A. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood: 2011; 118 12 3212 3221
2. Zheng X. L. Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost: 2013; 11 01 11 23
3. Levy G. G., Motto D. G., Ginsburg D. ADAMTS13 turns 3. Blood: 2005; 106 1 11 17 (Pubitemid 40967168)
4. George J. N. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med: 2006; 354 18 1927 1935 (Pubitemid 43872694)
5. Kremer Hovinga J. A., Vesely S. K., Terrell D. R., Lämmle B., George J. N. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood: 2010; 115 8 1500 1511, quiz 1662
6. Schiviz A., Wuersch K., Piskernik C., et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood: 2012; 119 25 6128 6135
7. Klaus C., Plaimauer B., Studt J. D., et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood: 2004; 103 12 4514 4519 (Pubitemid 38745978)
8. Tarr P. I., Gordon C. A., Chandler W. L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet: 2005; 365 9464 1073 1086 (Pubitemid 40386785)
9. Lenting P. J., Casari C., Christophe O. D., Denis C. V. von Willebrand factor: the old, the new and the unknown. J Thromb Haemost: 2012; 10 12 2428 2437
10. De Meyer S. F., Stoll G., Wagner D. D., Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke: 2012; 43 2 599 606
11. Zhao B. Q., Chauhan A. K., Canault M., et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood: 2009; 114 15 3329 3334
12. Khan M. M., Motto D. G., Lentz S. R., Chauhan A. K. ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice. J Thromb Haemost: 2012; 10 8 1665 1671
13. Crawley J. T., Lane D. A., Woodward M., Rumley A., Lowe G. D. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost: 2008; 6 4 583 588 (Pubitemid 351418945)
14. Matsukawa M., Kaikita K., Soejima K., et al. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol: 2007; 100 5 758 763 (Pubitemid 47268262)
15. Doi M., Matsui H., Takeda H., et al. ADAMTS13 safeguards the myocardium in a mouse model of acute myocardial infarction. Thromb Haemost: 2012; 108 6 1236 1238
16. De Meyer S. F., Savchenko A. S., Haas M. S., et al. Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood: 2012; 120 26 5217 5223
17. Gandhi C., Motto D. G., Jensen M., Lentz S. R., Chauhan A. K. ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. Blood: 2012; 120 26 5224 5230
18. Chauhan A. K., Motto D. G., Lamb C. B., et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med: 2006; 203 3 767 776
19. Crescente M., Thomas G. M., Demers M., et al. ADAMTS13 exerts a thrombolytic effect in microcirculation. Thromb Haemost: 2012; 108 3 527 532
20. Martin J. N. Jr, Rose C. H., Briery C. M. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol: 2006; 195 4 914 934 (Pubitemid 44415627)
21. Lattuada A., Rossi E., Calzarossa C., Candolfi R., Mannucci P. M. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica: 2003; 88 9 1029 1034 (Pubitemid 37151154)
22. Pourrat O., Coudroy R., Pierre F. ADAMTS13 deficiency in severe postpartum HELLP syndrome. Br J Haematol: 2013; 163 3 409 410
23. Keiser S. D., Boyd K. W., Rehberg J. F., et al. A high LDH to AST ratio helps to differentiate pregnancy-associated thrombotic thrombocytopenic purpura (TTP) from HELLP syndrome. J Matern Fetal Neonatal Med: 2012; 25 7 1059 1063
24. Katz L., de Amorim M. M., Figueiroa J. N., Pinto e Silva J. L. Postpartum dexamethasone for women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol: 2008; 198 3 e1 e8
25. van den Born B. J., Koopmans R. P., van Montfrans G. A. The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. Am J Hypertens: 2007; 20 8 900 906 (Pubitemid 47176352)
26. Immink R. V., van den Born B. J., van Montfrans G. A., Koopmans R. P., Karemaker J. M., van Lieshout J. J. Impaired cerebral autoregulation in patients with malignant hypertension. Circulation: 2004; 110 15 2241 2245 (Pubitemid 39372508)
27. van den Born B. J., Beutler J. J., Gaillard C. A., de Gooijer A., van den Meiracker A. H., Kroon A. A. Dutch guideline for the management of hypertensive crisis - 2010 revision. Neth J Med: 2011; 69 5 248 255
28. Patel A., Patel H., Patel A. Thrombotic thrombocytopenic purpura: the masquerader. South Med J: 2009; 102 5 504 509
29. van den Born B. J., van der Hoeven N. V., Groot E., et al. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension: 2008; 51 4 862 866 (Pubitemid 351654696)
30. Pappelbaum K. I., Gorzelanny C., Grässle S., et al. Ultralarge von Willebrand factor fibers mediate luminal Staphylococcus aureus adhesion to an intact endothelial cell layer under shear stress. Circulation: 2013; 128 1 50 59
31. Chauhan A. K., Kisucka J., Brill A., Walsh M. T., Scheiflinger F., Wagner D. D. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med: 2008; 205 9 2065 2074
32. Ono T., Mimuro J., Madoiwa S., et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood: 2006; 107 2 528 534 (Pubitemid 43076375)
33. Levi M., van der Poll T., Schultz M. New insights into pathways that determine the link between infection and thrombosis. Neth J Med: 2012; 70 3 114 120
34. Claus R. A., Bockmeyer C. L., Budde U., et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost: 2009; 101 2 239 247
35. de Mast Q., Groot E., Asih P. B., et al. ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria. Am J Trop Med Hyg: 2009; 80 3 492 498
36. Larkin D., de Laat B., Jenkins P. V., et al. Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition. PLoS Pathog: 2009; 5 3 e1000349
37. Löwenberg E. C., Charunwatthana P., Cohen S., et al. Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13. Thromb Haemost: 2010; 103 1 181 187
38. Starke R. D., Ferraro F., Paschalaki K. E., et al. Endothelial von Willebrand factor regulates angiogenesis. Blood: 2011; 117 3 1071 1080
39. Terraube V., Pendu R., Baruch D., et al. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost: 2006; 4 3 519 526
40. Mannucci P. M. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. J Thromb Haemost: 2006; 4 4 721 723
41. Lisman T., Leebeek F. W. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg: 2007; 24 4 250 258 (Pubitemid 47174040)
42. Lisman T., Bongers T. N., Adelmeijer J., et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology: 2006; 44 1 53 61 (Pubitemid 44049138)
43. Mannucci P. M., Canciani M. T., Forza I., Lussana F., Lattuada A., Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood: 2001; 98 9 2730 2735
44. Uemura M., Fujimura Y., Matsumoto M., et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost: 2008; 99 6 1019 1029 (Pubitemid 351810483)
45. Walsh K. A., Lewis D. A., Clifford T. M., et al. Risk factors for venous thromboembolism in patients with chronic liver disease. Ann Pharmacother: 2013; 47 3 333 339
46. Chen J., Reheman A., Gushiken F. C., et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest: 2011; 121 2 593 603